|
1000
|
Abstract/Summary
|
-
The Preg-CoV platform trial aimed to identify the optimal time to administer COVID-19 vaccines in pregnancy to best protect pregnant women against COVID-19. The trial is led by St George’s, University of London and provides clinical trial data on the immune response to vaccination in women and their infants, when given at different dose intervals and at different times in pregnancy. The trial involved over 300 pregnant women who were vaccinated with available COVID-19 vaccines. They were closely monitored by health professionals throughout their pregnancy and following the birth, with the safety of the women and their babies being of utmost importance. The Preg-CoV participants were between 18 and 44 years old, had no major health conditions and were between 13 and 34 weeks pregnant on the day of vaccination. They received 2 doses of a COVID-19 vaccine in pregnancy – or one booster dose if they had already received primary vaccination. In this webinar, Eva Galiza and Paul Heath will introduce the Preg-CoV trial, explain details of the study protocol, describe the challenges of running a pregnancy vaccine trial in a pandemic, evaluate results and conclusions and discuss the benefits of an adaptive pregnancy vaccine platform for future vaccine evaluations.
|
